| EN
For the years of 2017, 2018 and 2019, Simcere's research and development costs accounted for 5.5%, 9.9% and 14.2%, respectively, of its total revenue for the total periods. We have established three R&D centers including one in Nanjing, Jiangsu, one in Shanghai and one in Boston, the United States. With the approval of the Ministry of Science and Technology, we also established a national key laboratory of translational medicine and innovative pharmaceuticals.

Global R&D Center Layout

Boston R&D Center

Primarily focuses on innovative and advanced therapies, particularly cell therapy

Nanjing R&D Center

Focuses on innovative and high entry-barrier generic pharmaceuticals

Shanghai R&D Center

Focuses on innovative pharmaceuticals

R&D Pipeline

At present, we had nearly 50 innovative product candidates in different stages of development, including small molecule pharmaceuticals, large molecule pharmaceuticals and CAR T-cell therapies, among which over 10 product candidates were at clinical stage, had submitted NDA or had obtained NDA pending market launch.

Simcere was approved by the Ministry of Science and Technology of the PRC in October 2015 to establish the only state key laboratory of translational medicine and innovative pharmaceuticals in the PRC pharmaceutical industry. Since its establishment, we have made rapid progress in critical technologies breakthroughs, new drug development, talent training and team building.
This laboratory focuses on the translational medicine and precision medicine-based research and development of innovative pharmaceuticals for the treatment of oncology, central nervous system diseases, autoimmune diseases and infectious diseases.
The laboratory’s several goals include establishing key translational medicine technologies for new drug development, creating an integrated platform for general translational medicine technology research, and providing exemplary models of platform setup (including required key technologies) and industry standards for new drug development within translational medicine.

Massachusetts is home to 19% of the top pharmaceutical product pipelines in the United States and 9% globally. The state capital, Boston, in particular holds a dominating position in the global life sciences community.

Simcere’s Boston R&D Center focuses on the world's cutting-edge cell and gene therapies, and with its team of pioneering scientists, it remains dedicated to building a world-class R&D center. Utilizing the world's state-of-the-art technologies, we are rapidly building several cutting-edge technology platforms for cell and gene therapies and thereby making the Boston R&D Center a powerful pipeline driver for Simcere through the institute’s fast and efficient project promotion system.